TSE:AUP Aurinia Pharmaceuticals (AUP) Stock Price, News & Analysis → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free AUP Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$16.76▼C$16.7652-Week Range N/AVolume4.61 million shsAverage Volume229,895 shsMarket CapitalizationC$2.15 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aurinia Pharmaceuticals alerts: Email Address Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Aurinia Pharmaceuticals Stock (TSE:AUP)Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Read More Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. AUP Stock News HeadlinesFebruary 29, 2024 | barrons.comAurinia Pharmaceuticals Inc.February 15, 2024 | msn.comAurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock BuybackApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 15, 2024 | msn.comExclusive-Kidney drug developer Aurinia fails to clinch a sale, sources sayFebruary 15, 2024 | msn.comAurinia Pharma GAAP EPS of -$0.19 misses by $0.03, revenue of $45.1M misses by $0.06MFebruary 15, 2024 | msn.comAurinia drops after Q4 miss; strategic review failsFebruary 15, 2024 | reuters.comAurinia to stop development of immunotherapies after strategic reviewFebruary 15, 2024 | reuters.comExclusive: Kidney drug developer Aurinia fails to clinch a sale, sources sayApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 14, 2024 | msn.comAurinia Pharma Q4 2023 Earnings PreviewFebruary 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)February 8, 2024 | msn.comAurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseNovember 13, 2023 | benzinga.comAurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in JapanNovember 13, 2023 | markets.businessinsider.comAurinia Says Its Partner Otsuka Filed NDA For Voclosporin In JapanNovember 6, 2023 | markets.businessinsider.comStrong 3Q Performance and Growing Lupkynis Sales Bolster Aurinia Pharmaceuticals’ Buy Rating: An In-depth Analysis by David Martin, PhDNovember 2, 2023 | seekingalpha.comAurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call TranscriptSeptember 27, 2023 | msn.comAurinia Pharmaceuticals: Reassessing As It Gains TractionAugust 3, 2023 | seekingalpha.comAurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Call TranscriptJuly 18, 2023 | msn.comAurinia Pharmaceuticals Stock Returns To A Rising Relative StrengthJune 29, 2023 | benzinga.comAurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueJune 16, 2023 | msn.comAurinia Pharmaceuticals: Still In The Game With Lupkynis SalesMay 18, 2023 | msn.comAurinia Pharmaceuticals Earnings Perspective: Return On Capital EmployedMay 17, 2023 | technews.tmcnet.comMKT Capital Thanks Fellow Shareholders for Their Strong Support at Aurinia's 2023 Annual MeetingMay 9, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Sizeable Upgrade To Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ForecastsMay 6, 2023 | markets.businessinsider.comBloom Burton Remains a Buy on Aurinia Pharmaceuticals (AUPH)May 5, 2023 | technews.tmcnet.comMKT Capital Issues Statement Regarding Aurinia's Disappointing First Quarter 2023 Financial ResultsMay 4, 2023 | finance.yahoo.comAurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational ResultsSee More Headlines Receive AUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorComputer and Technology Industry Technical & System Software Sub-IndustryN/A Current SymbolTSE:AUP Previous SymbolTSE:ISA CUSIPN/A CIKN/A Webwww.auriniapharma.com Phone+1-250-7084272FaxN/AEmployees294Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.69 Current Ratio11.93 Quick Ratio11.02 Sales & Book Value Annual SalesC$57.59 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.75 Book ValueC$2.59 per share Price / BookN/AMiscellaneous Outstanding Shares128,396,000Free FloatN/AMarket CapC$2.15 billion OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 51)Pres, CEO & Director Comp: $1.39MMr. Joseph M. Miller CPA (Age 47)Chief Financial Officer Comp: $614.27kMr. Matthew Maxwell Donley M.B.A. (Age 52)Exec. VP of Operations & Strategy Comp: $627.51kMr. Stephen P. Robertson (Age 39)Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer Comp: $193.43kMr. Massimiliano Colao (Age 56)Chief Commercial Officer Comp: $719.79kDr. Glenn SchulmanSr. VP of Corp. Communications & Investor RelationsMr. Chris HaysVP of MarketingMr. Fran LynchVP of SalesDr. Robert B. Huizinga M.Sc. (Age 56)Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C), Exec. VP of Research Mr. Michael R. Martin (Age 49)Chief Bus. Officer More ExecutivesKey CompetitorsAbsolute Software Co. (ABT.TO)TSE:ABTLifeWorksTSE:LWRKBlackBerryTSE:BBDoceboTSE:DCBOMitel NetworksTSE:MNWView All Competitors AUP Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include ARC Resources (ARX), Enbridge (ENB), Aurinia Pharmaceuticals (AUPH), Brookfield Renewable Partners (BEP.UN), Costco Wholesale (COST), Parkland (PKI), Allena Pharmaceuticals (ALNA), Algonquin Power & Utilities (AQN), Brookfield Infrastructure Partners (BIP.UN) and Granite Real Estate Investment Trust (GRT.UN). How do I buy shares of Aurinia Pharmaceuticals? Shares of AUP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:AUP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
